Graph

A tremendous thank you to the team at Bleed Design Studio for their fresh ideas and precise implementation of helping us visualize the complexity of our work!

New look, same mission. 🧑‍🚀 🚀

We’re excited to debut our updated website that reflects who we are and the work we are doing at Graph: unafraid and boldly confronting the dynamic behavior of immune biology head on.

Check it out 🌐 www.graphtx.com

Thanks to the organizers of this Keystone Symposia meeting! We’re already looking forward to the next one. ➕✖️

To better understand how immune cells jointly behave in a complex inflammatory environment, the Graph team profiled millions of primary-immune cells in a disease-relevant systemic inflammation condition, and identified numerous hits that affect inflammasome modulation in monocytes. 📊 💡

Focusing on the NLR-specific endpoint of endogenous ASC-speckling in sterile inflammation, we mapped systemic responses by using our platform for fast, patient-first I&I discovery. 🗺️ 📍

In our latest talk & poster presentation at the Keystone Autoimmunity & Autoinflammation symposium, Graph’s co-founder & CSO Bojan Vilagos presented our generalizable & scalable approach for discovering shared mechanisms across disease contexts. 🧬 ⚙️

Full poster here 👉 graphtx.com/inflammasome...

Together with Parse’s GigaLab technology that can profile hundreds of millions of cells and Graph’s lab-in-the-loop platform that can systematically select and test perturbations across a wide range of disease contexts, we are reshaping the future of AI-first drug discovery. ➕✖️

Immune-mediated & autoimmune diseases are notoriously difficult to model. By leveraging primary patient-derived cells rather than cell lines or animal models, this partnership allows the team at Graph to identify the most promising disease mechanisms, drug targets, & biomarkers early in discovery.

Parse Biosciences and Graph are partnering to create the world's most comprehensive immune cell perturbation atlas aimed at revealing immune system dysfunction for curative drug discovery. 🧬 🗺️

➡️ Read more: www.parsebiosciences.com/news/parse-b...

Together with Parse’s GigaLab technology that can profile hundreds of millions of cells and Graph’s lab-in-the-loop platform that can systematically select and test perturbations across a wide range of disease contexts, we are reshaping the future of AI-first drug discovery. ➕✖️

Immune-mediated & autoimmune diseases are notoriously difficult to model. By leveraging primary patient-derived cells rather than cell lines or animal models, this partnership allows the team at Graph to identify the most promising disease mechanisms, drug targets, & biomarkers early in discovery.

Fantastic panel at the Evotec Breakfast Reception in SF! Graph co-founder @gregvladimer.bsky.social shared insights alongside leaders from @isomorphiclabs.bsky.social & @medra-ai.bsky.social about how AI helps to unlock disease mechanisms & supports the development of future bio discoveries. 🚀

Poster title:
“Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets”

📍 Poster session 1
📅 20 January 2026
💬 Presenting author: Bojan Vilagos

🏔️ Hey Colorado, we’ll be up in the Rockies from 19 - 22 January 2026 for the Autoimmunity & Autoinflammation symposium! We’re looking forward to showcasing our approach of using advanced imaging & data modeling to find clinically-relevant targets & pathways for immune diseases in our latest poster.

🌊 ⛵ Hey San Francisco, on 13 January 2026 adjacent to the 44th Annual JPM Healthcare Conference, Graph’s co-founder and CEO Greg Vladimer will be speaking on Evotec's panel “Precision at Scale: AI’s impact on Drug Discovery." Let us know if you are in San Francisco and let’s talk techbio!

Just last week, we had a group retreat (aka Graph Con) to a mountain hut in the Alps 🇦🇹. We spent some time honing our cooking skills, enjoying the wintry landscape, and forging our 2026 strategy around immune dysfunction mapping.

We’re already energized for 2026, and we’re just getting started. 💫

Thank you to everyone who attended our AI x Bio meetup last week in Berlin! We had a great time catching up with old friends and making new connections. 🪩 🕺

👏 A huge thank you to all of our cohosts, including @Merantix AI Campus, Merantix Capital, CytoData, and @techbio.bsky.social support!

Building the Data Foundation to Scale Precision Immunology Towards context-conditioned foundation models of immune dysfunction

What does it takes to build real prediction power for precision immunology? Hint: it's about mapping immune dysfunction and scaling what's relevant.

➡️ Have a look at what we're building at Graph: graphtx.substack.com/p/building-t...

Thanks to everyone who came by our poster session! If you missed us there or want to learn more, you can view our full poster online: graphtx.com/Graph_CytoDa...

By using rheumatoid arthritis (RA) as a case study, the Graph team demonstrates a generalizable framework that can work in iterative cycles of lab experimentation and prediction, i.e. a lab-in-the-loop approach 🔁, to systematically understand mechanisms and drivers of the disease.

Immune-mediated diseases are highly complex and heterogeneous, which makes the discovery of precision medicines difficult. In Graph’s most recent poster at #CytoData2025, our research team showcased our systematic approach to address this challenge. 🎯

Berlin AI x Bio Meetup · Luma Graph Therapeutics, Merantix Capital, and TechBio Transformers (TBT) are bringing together techbio enthusiasts and experts in Berlin for a meetup, timed…

Bonus: meet us one day before the start of the symposium on 19 November at our Berlin AI x Bio Meetup. 👇

📅 19 November 2025, 18:30
📍 Merantix AI Campus, Berlin
🎟️ Sign up: lu.ma/u4i3i1i3

The poster is entitled: Decoding the functional and molecular niche of immune-mediated disease for iterative target discovery.

📅 Thursday, 20 November, 19:00 - 20:00
💬 Presenting author: @izepb.bsky.social

Hey Berlin, we’ll be in town from 20 - 21 November for CytoData 2025! If you want to know more about how we are decoding the functional and molecular niche of immune-mediated diseases for iterative target discovery, come by our poster session to learn more!

Meet the team behind Graph and say hello to @izepb.bsky.social, Principal Scientist! 🧬⛰️

Ize is helping us scale new heights where ML meets biology, one complex system at a time. ➕✖️

Berlin AI x Bio Meetup · Luma Graph Therapeutics, Merantix Capital, and TechBio Transformers (TBT) are bringing together techbio enthusiasts and experts in Berlin for a meetup, timed…

​You’re invited to join us for an evening to connect with others building at the intersection of biology, technology, and AI:

📅 19 November 2025, 18:30
📍 Merantix AI Campus, Berlin
👉 Sign up: lu.ma/u4i3i1i3

We’re excited to see you there and to talk about the future of techbio with you! 💡⚙️

By laying the groundwork with this collaboration, we’ll be able to continue to drive techbio innovation and create new opportunities that can transform how therapies are developed for patients with immune-mediated diseases worldwide. 🚀🌟

This partnership combines our AI-driven lab-in-the-loop approach with BIIE’s immune engineering expertise. By sharing resources, data, & insights, the goal is to jointly bridge the gap between lab discoveries & clinical impact, addressing critical unmet needs in the inflammation & immunology space.

✨ Some exciting news: We’re announcing a strategic partnership with the Botnar Institute of Immune Engineering (BIIE) to accelerate the development of precision medicines for immune-mediated diseases!

To learn more, reach out for a meeting or drop by our presentation:

📅 When: 5 November, 10:40
🎤 Speaker: Gregory Vladimer
📍 Where: Presenting Company Theater 1